These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277 [TBL] [Abstract][Full Text] [Related]
14. Characterization of long-term effector-memory T-cell responses in patients with resected high-risk melanoma receiving a melanoma Peptide vaccine. Chiong B; Wong R; Lee P; Delto J; Scotland R; Lau R; Weber J J Immunother; 2004; 27(5):368-79. PubMed ID: 15314545 [TBL] [Abstract][Full Text] [Related]
15. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186 [TBL] [Abstract][Full Text] [Related]
16. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Harlin H; Kuna TV; Peterson AC; Meng Y; Gajewski TF Cancer Immunol Immunother; 2006 Oct; 55(10):1185-97. PubMed ID: 16468035 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884 [TBL] [Abstract][Full Text] [Related]
18. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. Sanderson K; Scotland R; Lee P; Liu D; Groshen S; Snively J; Sian S; Nichol G; Davis T; Keler T; Yellin M; Weber J J Clin Oncol; 2005 Feb; 23(4):741-50. PubMed ID: 15613700 [TBL] [Abstract][Full Text] [Related]
19. Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. Retseck J; Nasr A; Lin Y; Lin H; Mendiratta P; Butterfield LH; Tarhini AA J Transl Med; 2018 Jul; 16(1):184. PubMed ID: 29973204 [TBL] [Abstract][Full Text] [Related]
20. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. Fourcade J; Kudela P; Andrade Filho PA; Janjic B; Land SR; Sander C; Krieg A; Donnenberg A; Shen H; Kirkwood JM; Zarour HM J Immunother; 2008 Oct; 31(8):781-91. PubMed ID: 18779741 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]